Overview
Compare with iTonic Holdings Ltd, Nexalin Technology, Inc. or GUIDED THERAPEUTICS INC, or pick any stock.
- TickerPOSC on OTC1
- IndustryElectromedical & Electrotherapeutic Apparatus1
- HeadquartersWestmount, Illinois1
- Incorporated inTX2
- Business address530 Oakmont Lane, Westmount, Il 605592
- Filer categoryNon-accelerated filer, Smaller reporting company2
See how the biggest companies compare on our leaderboards
PET imaging and a growing presence in oncology and neurology, Positron stands at the forefront of innovation in nuclear medicine.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue95¢$2.6M
- Interest5¢$125.3K
Out of $461.5K in revenue.4 The company lost money this year.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Sales | $461.5K | $587.5K |
| Cost of sales | $2.6M | $929.5K |
| Gross loss | -$2.1M | -$342.0K |
| General and administrative expenses | $8.4M | $1.9M |
| Loss from operations | -$10.5M | -$2.2M |
| Interest expense | -$125.3K | -$142.4K |
| Interest income | $35.4K | |
| Amortization of debt discount | -$31.7K | |
| Loss on lease termination | -$15.0K | |
| Total other income (expense) - net | -$104.9K | -$174.1K |
| Net loss | -$10.6M | -$2.4M |
| Loss per share - diluted | -$0.34 | -$0.09 |
| Loss per share - basic | -$0.34 | -$0.09 |
| Weighted average number of shares - diluted | 30.9M shares | 26.0M shares |
| Weighted average number of shares - basic | 30.9M shares | 26.0M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.4
| Period ending | 2025-12-31 | 2025-10-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $2.5M | $69.8K | ||
| Accounts receivable | $8.3K | $16.7K | ||
| Inventory | $680.0K | $1.3M | ||
| Prepaids and other | $130.4K | $9.1K | ||
| Total Current Assets | $3.3M | $1.4M | ||
| Property and equipment - net | $105.8K | $34.1K | ||
| Operating lease - right-of-use asset | $179.7K | $39.0K | ||
| Deposits | $375.0K | $375.0K | ||
| Total Assets | $4.0M | $1.8M | ||
| Accounts payable and accrued expenses | $81.5K | $7.7K | ||
| Accounts payable and accrued expenses - related party | $407.0K | $326.0K | ||
| Deferred revenue | $120.0K | $66.3K | ||
| Note payable - related party - net | $1.2M | $1.4M | ||
| Operating lease liability | $30.6K | $19.9K | ||
| Convertible advance payable | $563.0K | $563.0K | ||
| Total Current Liabilities | $2.4M | $2.4M | ||
| Operating lease liability | $153.7K | $24.3K | ||
| Total Long Term Liabilities | $153.7K | $24.3K | ||
| Total Liabilities | $2.6M | $2.5M | ||
| Common stock - $0.0001 par value, 100,000,000 shares authorized 32,799,451 and 27,305,008 shares issued and outstanding, respectively | $3.3K | $2.7K | ||
| Additional paid-in capital | $146.4M | $133.0M | ||
| Accumulated deficit | -$144.9M | -$134.3M | ||
| Less: treasury stock at cost - 750 and 750 shares, respectively | -$375 | -$375 | ||
| Total Stockholders Equity (Deficit) | $1.4M | -$656.7K | -$510.3K | |
| Total Liabilities and Stockholders Equity (Deficit) | $4.0M | $1.8M | ||
| Preferred stock, par value | $0.00 | $0.00 | $0.00 | |
| Preferred stock, authorized | 10.0M shares | 10.0M shares | 10.0M shares | |
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 100.0M shares | 100.0M shares | 100.0M shares | |
| Common stock, shares outstanding | 32.8M shares | 27.3M shares | ||
| Common stock, shares issued | 32.8M shares | 27.3M shares |
| Period ending | 2025-12-31 | 2025-10-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $2.5M | $69.8K | ||
| Accounts receivable | $8.3K | $16.7K | ||
| Inventory | $680.0K | $1.3M | ||
| Prepaids and other | $130.4K | $9.1K | ||
| Total Current Assets | $3.3M | $1.4M | ||
| Property and equipment - net | $105.8K | $34.1K | ||
| Operating lease - right-of-use asset | $179.7K | $39.0K | ||
| Deposits | $375.0K | $375.0K | ||
| Total Assets | $4.0M | $1.8M | ||
| Accounts payable and accrued expenses | $81.5K | $7.7K | ||
| Accounts payable and accrued expenses - related party | $407.0K | $326.0K | ||
| Deferred revenue | $120.0K | $66.3K | ||
| Note payable - related party - net | $1.2M | $1.4M | ||
| Operating lease liability | $30.6K | $19.9K | ||
| Convertible advance payable | $563.0K | $563.0K | ||
| Total Current Liabilities | $2.4M | $2.4M | ||
| Operating lease liability | $153.7K | $24.3K | ||
| Total Long Term Liabilities | $153.7K | $24.3K | ||
| Total Liabilities | $2.6M | $2.5M | ||
| Common stock - $0.0001 par value, 100,000,000 shares authorized 32,799,451 and 27,305,008 shares issued and outstanding, respectively | $3.3K | $2.7K | ||
| Additional paid-in capital | $146.4M | $133.0M | ||
| Accumulated deficit | -$144.9M | -$134.3M | ||
| Less: treasury stock at cost - 750 and 750 shares, respectively | -$375 | -$375 | ||
| Total Stockholders Equity (Deficit) | $1.4M | -$656.7K | -$510.3K | |
| Total Liabilities and Stockholders Equity (Deficit) | $4.0M | $1.8M | ||
| Preferred stock, par value | $0.00 | $0.00 | $0.00 | |
| Preferred stock, authorized | 10.0M shares | 10.0M shares | 10.0M shares | |
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 100.0M shares | 100.0M shares | 100.0M shares | |
| Common stock, shares outstanding | 32.8M shares | 27.3M shares | ||
| Common stock, shares issued | 32.8M shares | 27.3M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$10.6M | -$2.4M |
| Amortization of operating lease - right-of-use asset | $27.1K | $16.1K |
| Amortization of debt discount | $31.7K | |
| Depreciation expense | $27.4K | $22.1K |
| Write-down of inventory to net realizable value | $576.9K | |
| Stock based compensation - employee stock options | $5.0M | |
| Stock issued for services | $177.0K | $525.0K |
| Loss on lease termination | $15.0K | |
| Imputed interest expense on debt | $4.9K | |
| Imputed interest expense on debt - related parties | $2.9K | $2.8K |
| Cash paid for lease termination | -$20.0K | |
| Accounts Receivable | $8.3K | $5.4K |
| Prepaids | -$121.3K | -$7.3K |
| Deposits | -$100.0K | |
| Accounts payable and accrued expenses | $73.8K | -$13.8K |
| Accounts payable and accrued expenses - related party | $122.4K | $134.7K |
| Deferred revenue | $53.7K | $41.7K |
| Operating lease liability | -$22.7K | -$15.0K |
| Net cash used in operating activities | -$4.7M | -$1.7M |
| Purchase of fixed assets | -$99.0K | |
| Net cash used in investing activities | -$99.0K | |
| Proceeds from stock issued for cash | $10.0M | $1.4M |
| Cash paid to repurchase and retire common stock | -$2.5M | |
| Proceeds from issuance of note payable - related party | $100.0K | |
| Proceeds from issuance of note payable | $300.0K | |
| Proceeds from note payable - related party | $100.0K | |
| Repayments on notes payable - related party | -$350.0K | -$100.0K |
| Net cash provided by financing activities | $7.2M | $1.7M |
| Net increase (decrease) in cash and cash equivalents | $2.5M | -$30.9K |
| Forgiveness of accrued interest payable - related party | $41.4K | |
| Right-of-use asset obtained in exchange for new operating lease liability | $196.0K | |
| Termination of ROU operating lease asset and liability | $28.2K | |
| Conversion of Series A preferred stock to common stock | $435.1K | |
| Conversion of Series B preferred stock to common stock | $192.0K | |
| Conversion of debt to common stock | $300.0K |
No quarter-by-quarter statement was filed.
What it owns
What POSITRON CORP reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $227.9K4 Dec 31, 2025 | $128.8K4 Dec 31, 2024 | +76.9% |
| Accumulated depreciation | $122.1K4 Dec 31, 2025 | $94.7K4 Dec 31, 2024 | +28.9% |
| Property and equipment, net | $105.8K4 Dec 31, 2025 | $34.1K4 Dec 31, 2024 | +210.1% |
| Operating-lease assets (leased space) | $179.7K4 Dec 31, 2025 | $39.0K4 Dec 31, 2024 | +361.1% |
Investments
Inventory
| Item | Latest | A year before | Change |
|---|---|---|---|
| Inventory, total | $680.0K4 Dec 31, 2025 | $1.3M4 Dec 31, 2024 | −45.9% |
| Finished goods | $1.3M4 Dec 31, 2025 | $1.3M4 Dec 31, 2024 | 0% |
Properties, in its own words
On July 8, 2025, the Company entered into a lease agreement (the “Lease”) with GSMS 2015-GC34 Commerce Court LLC, a New York limited liability company (the “Lessor”) for the Company’s corporate headquarters, systems showroom, parts warehouse and testing facility. The amount of leased space at this location in North Tonawanda, New York is approximately 6,000 square feet.
The Company has a month to month operating lease for its Houston office where the Company tests components and maintains inventory parts. Monthly rent on the facility is $1,000.
Item 2 of the 10-K filed Mar 31, 2026.3
Leadership
Who has led POSITRON CORP, and when. Pick a name to see everywhere that person has worked.
Chief executive
Chief financial officer
- Chief executive officerPatrick G. Rooney Nov 8, 2011 to Sep 12, 20148
- PresidentPatrick G. Rooney Sep 13, 2011 to Sep 13, 20119
- PresidentSachio Okamura Nov 8, 2011 to Nov 8, 201110
- PresidentJoseph G. Oliverio Jan 4, 2006 to Sep 13, 201111
- Chief financial officerCorey N. Conn May 9, 2013 to Nov 6, 201412
Board members and other officers (7)
- [ ]Corey N. Conn May 11, 2011 to May 11, 201113
- [ ]Timothy M. Gabel May 11, 2011 to May 11, 201114
- VP. of PharmaceuticalsScott M. Stiffler May 12, 2011 to May 12, 201115
- Board memberCorey N. Conn May 11, 2011 to Nov 6, 201413
- Board memberJoseph G. Oliverio Sep 13, 2011 to Sep 13, 201116
- Board memberPatrick G. Rooney Sep 13, 2011 to Sep 12, 20149
- Board memberSachio Okamura Nov 8, 2011 to Nov 8, 201110
Timeline
- Oct 2, 20268-K Entered a material agreement; New debt or obligation; Unregistered sale of shares17
- Aug 18, 20268-K Entered a material agreement18
- Dec 30, 20258-K Entered a material agreement; Unregistered sale of shares19
- Dec 16, 20258-K Change of auditor20
- Nov 8, 2011New chief executive Patrick G. Rooney becomes CEO8
Filings
8 filings to the SEC since October 2021: 1 annual reports, 2 quarterly reports, 4 major events, 1 other. The latest 8:
- Oct 2, 20268-K EDGAR
- Aug 18, 20268-K EDGAR
- Aug 14, 202610-Q EDGAR
- May 15, 202610-Q EDGAR
- Mar 31, 202610-K EDGAR
- Dec 30, 20258-K EDGAR
- Dec 16, 20258-K EDGAR
- Nov 12, 202510-12G EDGAR
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
SEC filer profile
How POSITRON CORP is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARPOSITRON CORP1
- CIK0000844985
- Employer ID (EIN)76-00836223
- Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; a shell company3
- Incorporated inTexas3
- Fiscal year endsDecember 311
- Industry code (SIC)3845 Electromedical & Electrotherapeutic Apparatus1
- SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance1
- Business address530 Oakmont Lane, Westmount, IL 605591
- Phone28149271001
- Shares outstanding32,846,326 as of Aug 14, 20266
- Public float$21.9M as of Jun 30, 20253
- AuditorSalberg & Company, P.A., Boca Raton, Florida PCAOB ID 106; it also attests to the company’s internal control over financial reporting3
- On EDGAR sinceMay 15, 19961
- Filings325 in all: 8-K (51), 10QSB (35), 10-Q (27), 4 (27), UPLOAD (16), 3 (14), NT 10-Q (13), 10-Q/A (11)1
All 42 form types
10KSB (11), CORRESP (11), NT 10-K (10), 10-K/A (9), 10-K (8), S-8 (7), 10QSB/A (6), 10KSB/A (5), DEF 14A (5), PRE 14C (5), RW (5), 4/A (4), 424B3 (4), DEF 14C (4), SB-2/A (4), SC 13D (4), 5 (3), PRE 14A (3), PRER14C (3), SB-2 (3), D (2), S-3 (2), S-3/A (2), 10-12G (1), 10KSB40 (1), 10KSB40/A (1), 15-12G (1), 8-K/A (1), POS AM (1), PRER14A (1), REGDEX (1), RW WD (1), S-1 (1), SC 13D/A (1)
- Latest filingsAnnual report (10-K) Mar 31, 2026
Quarterly report (10-Q) Aug 14, 2026
Proxy statement (DEF 14A) Apr 27, 2006
Latest 8-K (8-K) Oct 2, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common Stock, par value $0.0001 | POSC |
From the cover page of the 10-K filed Mar 31, 2026 (Section 12(b) of the Exchange Act).3
Risk factors and legal proceedings
The risks POSITRON CORP names in Item 1A of its 10-K filed Mar 31, 2026: 7 risks under these headings, as written.3
- Risk Associated with Business Activities
- Strategic Initiatives
- Operational Execution
- Expansion in Nuclear Cardiology
- Expansion into Oncology and Additional Clinical Applications
- Strategic Partnerships and Business Development
- Capital Markets Strategy
- Requirements associated with being a reporting company will increase our costs significantly, as well as divert significant company resources and management attention.
- If we fail to maintain an effective system of disclosure controls and internal control over financial reporting, our ability to produce timely and accurate financial statements or comply with applicable regulations could be impaired.
- A Small Number of Large Stockholders and Thinly Traded Market.
- The downturn in the U.S. economy.
- Dependence upon third-party suppliers and the availability of certain radiopharmaceuticals.
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1SEC EDGARPOSITRON CORP filings on SEC EDGAR
- 2SEC EDGARPOSITRON CORP filings on SEC EDGAR
- 3
- 4SEC EDGARPOSITRON CORP 10-K for fiscal 2025
- 5SEC EDGARPOSITRON CORP 10-K for fiscal 2014
- 6SEC EDGARPOSITRON CORP 10-Q for fiscal 2025
- 7SEC EDGARPOSITRON CORP 10-Q for fiscal 2026
- 8
- 9SEC EDGARPatrick G. Rooney, President
- 10SEC EDGARSachio Okamura, President
- 11SEC EDGARJoseph G. Oliverio, President
- 12
- 13SEC EDGARCorey N. Conn, [ ]
- 14SEC EDGARTimothy M. Gabel, [ ]
- 15
- 16SEC EDGARJoseph G. Oliverio, Board member
- 17
- 18SEC EDGAREntered a material agreement
- 19
- 20SEC EDGARChange of auditor